How long does vitamin D take to work?

How it works

Heaney 2003 dose-response trial (PMID 12499343, AJCN 77(1):204-210, n=67 men, 20-week winter dosing in Omaha 41°N) established the canonical rate-of-rise: at steady state, serum 25-hydroxyvitamin D rises approximately 0.7 nmol/L per mcg/day of cholecalciferol (vitamin D3), equivalent to approximately 1.5 to 2.5 nmol/L per 100 IU/day. The widely cited 2.5 nmol/L (1 ng/mL) per 100 IU/day rule of thumb is operationally useful at low-to-moderate doses (up to around 2000 IU/day). The rate is notably higher when starting from severe deficiency (Sai 2011 reported around 9 nmol/L per 100 IU/day in deficient elderly) and lower when starting from already-sufficient levels.

Effective dose

These are population averages and individual responses vary substantially. Heaney 2003 (PMID 12499343) found equilibrium 25(OH)D rose around 0.7 nmol/L per microgram per day of cholecalciferol, roughly 1.75 nmol/L per 100 IU, from a baseline near 70 nmol/L. The relationship is curvilinear rather than linear, with a faster rise from a low starting point (Veugelers 2015). Practical timelines by starting level, drawn from UK regional NHS formularies and the Heaney and Drincic dose-response data, run as follows. Starting below 25 nmol/L on 4,000 IU per day for 12 weeks typically raises levels by 30 to 50 nmol/L or more. Starting between 25 and 50 nmol/L on 4,000 IU per day for 8 to 12 weeks typically brings levels above 50 nmol/L. Starting at 50 nmol/L or above, 400 to 800 IU per day holds levels in general adults. NHS loading regimens are 50,000 IU weekly for 6 to 8 weeks on prescription, or 4,000 IU daily for 8 to 12 weeks within the NHS upper limit, followed by 800 to 2,000 IU daily maintenance. Obese individuals require 2 to 3 times higher doses (Drincic 2013, PMID 24037880, JCEM, 67 obese subjects, 21 weeks; 1,000 IU per day produced a 12.4 ng/mL rise, 5,000 IU per day 27.8 ng/mL, 10,000 IU per day 48.1 ng/mL, approximately 2.5 IU/kg per ng/mL of 25(OH)D rise required). Higher BMI sequesters fat-soluble vitamin D in adipose tissue, reducing circulating levels for any given dose.

Forms compared

Lichen-derived vegan D3 is widely available in the UK; veganism does not require D2 in the modern UK supplement market. Activated forms (calcifediol, calcitriol) are clinical-supervision-only forms used in advanced kidney disease and specific conditions; not for self-supplementation. Powder and ethanol-based supplements absorb less well than oil-based or fish-oil-suspended forms.

Timing

Retesting before 8 weeks of consistent dosing typically captures a transient mid-rise level that does not reflect the eventual steady-state outcome. Single-test interpretation can mislead: 25-hydroxyvitamin D has substantial seasonal variation in the UK (peak in September, trough in February); a single test in winter may underestimate summer levels. Assay variability between laboratories (15-20% per SACN 2016) adds uncertainty to between-test comparisons; ideally use the same lab. Loading regimens compress total exposure into 6 to 8 weeks, but the same pharmacokinetic principle governs the rise, and daily maintenance afterwards reaches its own steady state over a further 8 to 12 weeks.

Safety profile

Loading regimens (50000 IU weekly for 6-8 weeks) are clinical-supervision territory; adjusted serum calcium at 1 month post-loading is standard to detect unmasked primary hyperparathyroidism and early hypercalcaemia. Individual responses vary; the rate-of-rise data is based primarily on healthy adult populations (predominantly Caucasian); responses in other populations may differ.

Special populations

Darker-skinned UK residents: see entry 16d95e91; rate-of-rise on standard doses is similar but baseline is typically much lower so absolute target time is longer. Chronic kidney disease (eGFR below 30): impaired 1-alpha-hydroxylation means standard cholecalciferol may show 25(OH)D rise without corresponding rise in active 1,25-dihydroxyvitamin D; activated forms (calcitriol, alfacalcidol) under specialist guidance only. Sarcoidosis: 1-alpha-hydroxylase activity in granulomas can produce hypercalcaemia at any 25(OH)D level; supplementation under specialist guidance only. Malabsorption conditions (coeliac, IBD, post-bariatric surgery): reduced absorption; higher doses typically required.

Interactions

Magnesium is required as a cofactor for both hepatic 25-hydroxylation and renal 1-alpha-hydroxylation (Uwitonze and Razzaque 2018, PMID 29480918); see entry a0e9dcf4 for the full activation mechanism. Inadequate magnesium can produce a misleading 25-hydroxyvitamin D level: total 25(OH)D may appear adequate but conversion to the active 1,25-dihydroxyvitamin D form is impaired. Where vitamin D supplementation does not produce expected clinical benefit despite acceptable blood levels, magnesium status assessment is reasonable. K2 considerations are covered in entry 457ce028.

Guideline positions

Sai 2011 reported around 9 nmol/L per 100 IU/day in deficient elderly populations. Uwitonze and Razzaque 2018 (PMID 29480918) for the magnesium cofactor mechanism. Tripkovic 2012 meta-analysis and Logan 2013 RCT for the D2 vs D3 efficacy difference. UK NHS regional formulary guidance for clinically supervised loading regimens typically specifies 50000 IU weekly for 6-8 weeks. The 100-150 nmol/L optimal target cited in some functional framings has no mainstream UK or international guideline support.

Practical framework

Weekly 50,000 IU regimens require a prescription; daily 4,000 IU regimens are available over the counter within the NHS upper limit. Obese adults typically need higher doses or longer durations and warrant specialist input above the NHS upper limit. Where vitamin D supplementation does not produce expected clinical benefit despite acceptable blood levels, magnesium status assessment is reasonable (Uwitonze and Razzaque 2018). Single-test interpretation can mislead: assay variability 15-20% between labs; seasonal variation substantial in UK; use the same lab for between-test comparisons. For readers who decide on a supplement, Nutri Tailor stocks [Vitamin D3 and K2](/products/vitamin-d3-k2) in the UK, with vegan and oil-drop versions on the same shelf. For readers who want vitamin D without K2 or a dose they can adjust drop by drop, Nutri Tailor stocks [vitamin D3 oil drops](/products/vitamin-d-liquid), 500 IU per four drops in an avocado oil base, made in the UK. To check your own result against the UK ranges, the Nutri Tailor [free blood test result interpreter](/apps/learn/free-blood-test-result-interpreter) reads ferritin and the iron panel, vitamin D, B12 and folate. This is a summary of published research, not personal health advice. Discuss any health or supplement decisions with a qualified healthcare professional, particularly during ongoing care, pregnancy, or with chronic conditions.

Common misconceptions

Claim: rate of rise is the same regardless of starting level. The relationship is curvilinear: steepest from severe deficiency (around 9 nmol/L per 100 IU/day in some deficient populations), flattest from already-high baseline (nearly flat at above 90 nmol/L starting).

Claim: routine retesting confirms supplementation is working. UK NHS and Endocrine Society 2024 guidance: routine retesting of asymptomatic individuals on standard doses is not recommended.

Claim: obese and lean individuals respond identically to a given dose. Drincic 2013 showed obese subjects need approximately 2-3x higher doses for equivalent 25(OH)D rises due to adipose sequestration of fat-soluble vitamin D.